These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30632108)

  • 1. Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
    Srinivas NR
    Clin Drug Investig; 2019 Jan; 39(1):105-107. PubMed ID: 30632108
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study".
    Akizawa T; Shimazaki R; Shiramoto M; Fukagawa M;
    Clin Drug Investig; 2019 Jan; 39(1):109-111. PubMed ID: 30632107
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
    Akizawa T; Shimazaki R; Shiramoto M; Fukagawa M;
    Clin Drug Investig; 2018 Oct; 38(10):945-954. PubMed ID: 30168004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Fukagawa M; Shimazaki R; Akizawa T;
    Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
    Akizawa T; Shimazaki R; Fukagawa M;
    PLoS One; 2018; 13(10):e0204896. PubMed ID: 30379826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
    Kawata T; Tokunaga S; Murai M; Masuda N; Haruyama W; Shoukei Y; Hisada Y; Yanagida T; Miyazaki H; Wada M; Akizawa T; Fukagawa M
    PLoS One; 2018; 13(4):e0195316. PubMed ID: 29614098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.
    Shigematsu T; Shimazaki R; Fukagawa M; Akizawa T;
    Clin Exp Nephrol; 2019 Feb; 23(2):258-267. PubMed ID: 30159688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evocalcet in the management of secondary hyperparathyroidism in dialysis patients.
    Parfrey PS
    Kidney Int; 2018 Oct; 94(4):661-662. PubMed ID: 30243312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan.
    Shigematsu T; Shimazaki R; Fukagawa M; Akizawa T
    Clin Pharmacol; 2018; 10():101-111. PubMed ID: 30254496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA
    Tokunaga S; Endo Y; Kawata T
    Nihon Yakurigaku Zasshi; 2019; 154(1):35-43. PubMed ID: 31308348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etelcalcetide for the treatment of secondary hyperparathyroidism.
    Hamano N; Komaba H; Fukagawa M
    Expert Opin Pharmacother; 2017 Apr; 18(5):529-534. PubMed ID: 28277829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients.
    Bashir SO; Omer HA; Aamer MA; Somialy R; Morsy MD
    Saudi J Kidney Dis Transpl; 2015 Nov; 26(6):1135-41. PubMed ID: 26586050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans.
    Narushima K; Maeda H; Shiramoto M; Endo Y; Ohtsuka S; Nakamura H; Nagata Y; Uchimura T; Kannami A; Shimazaki R; Fukagawa M; Akizawa T
    Clin Transl Sci; 2019 Jan; 12(1):20-27. PubMed ID: 30238620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants.
    Koiwa F; Yazawa R; Fukagawa M; Honda D; Akizawa T
    Drugs R D; 2022 Jun; 22(2):131-140. PubMed ID: 35338469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multi-Compartment Model Capturing the Pharmacokinetics of the Calcimimetic Cinacalcet.
    Schappacher-Tilp G; Fuertinger DH; Kotanko P
    Cell Physiol Biochem; 2019; 53(2):429-438. PubMed ID: 31424183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet Hydrochloride.
    Mostafa GAE; Al-Badr AA
    Profiles Drug Subst Excip Relat Methodol; 2017; 42():1-90. PubMed ID: 28431775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Calcimimetic drugs in stage 3-5 chronic kidney disease].
    Grzegorzewska AE; Niepolski L
    Pol Merkur Lekarski; 2012 Apr; 32(190):260-2. PubMed ID: 22708286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
    Verheyen N; Pilz S; Eller K; Kienreich K; Fahrleitner-Pammer A; Pieske B; Ritz E; Tomaschitz A
    Expert Opin Pharmacother; 2013 Apr; 14(6):793-806. PubMed ID: 23452174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.